Odevixibat

Odevixibat, sold under the brand name Bylvay among others, is a medication for the treatment of progressive familial intrahepatic cholestasis. It is taken by mouth. Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). It was developed by Albireo Pharma. The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver). Odevixibat was approved for medical use in the United States and in the European Union in July 2021. The U.S. Food and Drug Administration considers it to be a first-in-class medication.
Wikipedia contributors, "Odevixibat", Wikipedia, revision 1352067363, retrieved 20 November 2026, source, CC BY-SA 4.0.